Revolution Medicines Inc Hits 52-Week High
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 03 Dec 25
Source: 4
Revolution Medicines Inc's stock rose by 3.80%, reaching a 52-week high. This movement reflects positive market sentiment and investor interest.
The recent significant inflows into ETFs, including RVMD, indicate strong demand for the stock, contributing to its upward momentum. The overall market is also showing positive trends, with Nasdaq-100 and S&P 500 both up.
As investors continue to seek opportunities in biotech, the performance of Revolution Medicines Inc may attract further attention, potentially leading to more substantial gains in the future.
Analyst Views on RVMD
Wall Street analysts forecast RVMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 86.00 USD with a low forecast of 67.00 USD and a high forecast of 147.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 98.200
Low
67.00
Averages
86.00
High
147.00
Current: 98.200
Low
67.00
Averages
86.00
High
147.00
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
